Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06410293 PFS, PF-06410293 PFP · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06410293 PFS (Prefilled Syringe) | ACTIVE_COMPARATOR | PF-06410293 40 mg administered by Prefilled Syringe (PFS) |
| PF-06410293 PFP (Prefilled Pen) | ACTIVE_COMPARATOR | PF-06410293 40 mg administered by Prefilled pen |
| Name | Type | Description |
|---|---|---|
| PF-06410293 PFS | DEVICE | PF-06410293 40 mg administered subcutaneously by Prefilled syringe |
| PF-06410293 PFP | DEVICE | PF-06410293 40 mg administered subcutaneously by prefilled pen |
Inclusion Criteria: 1. Healthy female subjects and/or male subjects, who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood ...
PF-06410293 PFS, PF-06410293 PFP is an investigational drug being studied in healthy adult subjects. It is administered subcutaneously using a prefilled syringe or a prefilled pen. The drug is currently in Phase 1 clinical development and is not approved for any medical condition.
Pfizer, Inc. (NYSE: PFE) is developing PF-06410293 PFS, PF-06410293 PFP. The company conducted a Phase 1 clinical trial to evaluate the drug's administration via prefilled syringe or prefilled pen in healthy subjects.
PF-06410293 PFS, PF-06410293 PFP is in Phase 1 clinical development. A single Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities for any use.
PF-06410293 PFS, PF-06410293 PFP was studied in clinical trial NCT02572245, titled 'A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects.' This Phase 1 trial enrolled 164 participants in the United States and has been completed.
PF-06410293 PFS and PF-06410293 PFP are formulations of the drug PF-06410293. The PFS and PFP designations refer to the delivery devices: prefilled syringe and prefilled pen, respectively. The clinical trial NCT02572245 evaluated both formulations in healthy subjects.